Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
Major depressive disorder (MMD) is a leading cause of disability worldwide. Approximately one-third of patients with MDD fail to achieve response or remission leading to treatment-resistant depression (TRD). One of the psychopharmacological strategies to overcome TRD is using a combination of an ant...
Main Authors: | Manal E. Alkahtani, Alhassan H. Aodah, Omar A. Abu Asab, Abdul W. Basit, Mine Orlu, Essam A. Tawfik |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/6/891 |
Similar Items
-
Fast-Dissolving Nifedipine and Atorvastatin Calcium Electrospun Nanofibers as a Potential Buccal Delivery System
by: Hassa A. Alshaya, et al.
Published: (2022-02-01) -
Depression in acromegaly treated with escitalopram and cognitive therapy
by: De Sousa Avinash
Published: (2009-01-01) -
Female sexual dysfunction and Escitalopram antidepressant
by: Ali Mahran, et al.
Published: (2022-01-01) -
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
by: Wang G, et al.
Published: (2018-08-01) -
Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naïve patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns?
by: Harneet Kaur, et al.
Published: (2019-01-01)